Answers are grounded in this paper and cite their sources.
We investigated the efficacy and safety of dupilumab in Japanese patients aged ≥6 months to <18 years old with moderate-to-severe atopic dermatitis not adequately controlled with existing therapies.
No takes yet. Share an insight, caveat, or question.
Ebisawa et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: